Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today

被引：2
|
作者：
Bloomgarden, Zachary T. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2019年 / 157卷
关键词：
DIPEPTIDYL-PEPTIDASE-IV; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; METAANALYSIS; SITAGLIPTIN; RISK;
D O I：
10.1016/j.diabres.2019.107906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The right place for Sulphonylureas today: Part of 'Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus'
    Webb, David R.
    Davies, Melanie J.
    Jarvis, Janet
    Seidu, Sam
    Khunti, Kamlesh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 157
  • [2] Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
    Nielsen, LL
    DRUG DISCOVERY TODAY, 2005, 10 (10) : 703 - 710
  • [3] Incretins, incretinomimetics and DPP-IV inhibitors: glucose homeostasis and type 2 diabetes
    Virally, Marie
    Kevorkian, Jean-Philippe
    Guillausseau, Pierre-Jean
    SANG THROMBOSE VAISSEAUX, 2008, 20 (09): : 453 - 461
  • [4] Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
    Salvatore, Teresa
    Carbonara, Ornella
    Cozzolino, Domenico
    Torella, Roberto
    Sasso, Ferdinando C.
    CURRENT DIABETES REVIEWS, 2009, 5 (02) : 92 - 101
  • [5] Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes
    Benbow, John W.
    Andrews, Kim A.
    Aubrecht, Jiri
    Beebe, David
    Boyer, David
    Doran, Shawn
    Homiski, Michael
    Hui, Yu
    McPherson, Kirk
    Parker, Janice C.
    Treadway, Judith
    VanVolkenberg, Maria
    Zembrowski, William J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2220 - 2223
  • [6] QSAR studies on pyrrolidine amides derivatives as DPP-IV inhibitors for type 2 diabetes
    Xiaoyan Yang
    Minjie Li
    Qiang Su
    Milin Wu
    Tianhong Gu
    Wencong Lu
    Medicinal Chemistry Research, 2013, 22 : 5274 - 5283
  • [7] QSAR studies on pyrrolidine amides derivatives as DPP-IV inhibitors for type 2 diabetes
    Yang, Xiaoyan
    Li, Minjie
    Su, Qiang
    Wu, Milin
    Gu, Tianhong
    Lu, Wencong
    MEDICINAL CHEMISTRY RESEARCH, 2013, 22 (11) : 5274 - 5283
  • [8] Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes
    Hinnen, Deborah
    Nielsen, Loretta L.
    Waninger, Amy
    Kushner, Pamela
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2006, 19 (06) : 612 - 620
  • [9] Computational Identification of Inhibitors Against DPP-IV for Checking Type-2 Diabetes
    Gupta, Sarvesh Kumar
    Chaudhary, Kamal Kumar
    Raj, Utkarsh
    Mishra, Nidhi
    LETTERS IN DRUG DESIGN & DISCOVERY, 2017, 14 (01) : 66 - 73
  • [10] Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the treatment of type 2 diabetes
    Pan, Zhenhong
    Yang, Yan
    Zhang, Jingjing
    JOURNAL OF DIABETES, 2021, 13 (05) : 375 - 389
12345